The Effects of HER2 Positivity on Invasive Lobular Carcinoma of the Breast

UNIVERSITY OF MINNESOTA **Driven to Discover**



Background

Compared to invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC):

- May be less chemo responsive
- Has poorer survival rates
- Has rare HER2 positivity

Aim: to determine the effects of HER2 positivity on cancer outcomes in patients with ILC.

Methods

Retrospective cohort study

- National Cancer Database (2010-2017)
- Included: Stage I to III HER2+ ILC and IDC patients

To compare tumor, patient, and treatment characteristics between HER2+ ILC & IDC:

- Pearson's chi-squared test
- Cochrane Armitage test for trend
- Logistic regression model

Overall survival (OS) was evaluated

- Kaplan-Meier method
- Cox proportional hazard model (age, race, Charlson comorbidity index (CCI), year of diagnosis, tumor grade, hormone receptor status, treatment)

Results

- 4798 patients with HER2+ ILC
- 134904 patients with HER2+ IDC
- Most ILC tumors were pleomorphic (58.9%)

Patient and Tumor Characteristics

Patients with HER2+ ILC (vs IDC) were:

- Older
- Non-Hispanic white

But had similar CCI

HER2+ ILC (vs IDC) were more likely to be:

- ER and PR positive
- Lower grade
- Larger in size

But had similar nodal positivity rates

Table 1A	:			
HER2+				
Age at Diagnosis (years)				
18-44				
45-54				
55-64				
65+				
Race				
Non-Hispanic White				
Black				
Other				
Charlson Comorbidity Index				
0				
1				
2				
3				

HER2+

Estrogen Receptor Status			
Negative			
Positive			
Unknown			
Progesterone Receptor Status			
Negative			
Positive			
Unknown			
Grade			
1 and 2			
3			
Unknown			
Tumor Size			
< 2 cm			
2 - 5 cm			
> 5 cm			
Unknown			
Node Status			
Negative			
Positive			
Not Identified			

Saranya Prathibha, MD, Schelomo Marmor PhD, Corinne Praska, BS, McKenzie White, MD, Jacob Ankeny, MD, Christopher LaRocca, MD, Eric Jensen, MD, Todd Tuttle, MD, MS, Jane Yuet Ching Hui, MD, MS

> Division of Surgical Oncology, Department of Surgery Masonic Cancer Center, University of Minnesota

Patient characteristics


ILC		IDC		
n	%	n	%	P-value
				<.0001
331	7	24,384	18	
867	18	34,768	26	
1,375	29	37,214	28	
2,225	46	38,538	29	
				<.0001
3,825	80	95,597	71	
459	10	18,038	13	
514	11	21,269	16	
				0.30
4,037	84	114,846	85	
594	12	15,750	12	
120	3	3,059	2	
47	1	1,249	1	


Table 1B: Tumor characteristics

		IDC		
ILC	ILC			
n	%	n	%	p-value
				<.0001
399	8	43,672	32	
4395	92	91,022	67	
4	0	210	0	
				<.0001
1,196	25	63,360	47	
3,600	75	71,283	53	
2	0	261	0.2	
				<.0001
3431	72	51,622	38	
907	19	75,148	56	
460	10	8,134	6	
				<.0001
1,981	41	56,563	42	
2,010	42	62,758	47	
721	15	11,378	8	
86	2	4,205	3	
				<.0001
2,874	60	79,953	59	
1,582	33	46,540	35	
342	7	8,411	6	

HER2+		ILC		IDC		
		n	%	n	%	
Radiation						
	Yes	2,837	59	79,420	59	
	No	1,846	38	51,676	38	
	Unknown	115	2	3,808	3	
Chemotherapy						
	Yes	3456	72	106145	79	
	No	1324	28	28006	21	
	Unknown	18	1	753	1	

to those with HER2+ IDC







Comprehensive Cancer Center designated by the National Cancer Institute